Contact
ICL embraces "open innovation" with launch of technology accelaration program...
The Ultimate Win-Win for ICL, Entrepreneurs and the Global Village: ICL To Support the Development and Commercialization of Innovative, Sustainable Products and Processes Emerging from Academia and Start-ups –
Tel – Aviv, Israel, October 29, 2012 –ICL (TASE:ICL), a multinational fertilizer and specialty chemicals company, today announced that it has launched ICL Innovation Ltd., an Open Innovation program through which it will accelerate the development of sustainable new products and processes with the potential to drive the Company’s future growth.
“We are excited to harness the power of collaboration to create the ultimate ‘win-win’ scenario, helping scientists/entrepreneurs while accelerating the growth of our company – all by developing breakthrough new solutions for major global challenges,” commented Mr. Eyal Ginzberg, President of ICL’s IMI (TAMI) Institute for R&D and newly-appointed Chairman of ICL Innovation Ltd.
“Many innovative and promising ideas are never commercialized for lack of funding, project management, pilot facilities and commercialization expertise. Since we are so well established in each of these areas, we are ideally positioned to partner with scientists and entrepreneurs with great ideas in all parts of the world. By providing the right support, we will help them reduce the time it would otherwise require to take their projects from concept to industrial implementation. The Accelerator will also provide our company with a new source of innovative products and processes to augment our considerable R&D capabilities around the globe.”
ICL Innovation will solicit a selected number of product ideas and projects from a range of sources, including academic institutions, research institutes, technology cooperatives, incubators and venture capital funds. Each project selected will be “adopted” by an ICL segment, which will provide support and supervision to assure that the project remains practical and grounded. Upon successful commercialization, the segment will market the product and/or incorporate the process into its operations.
The ICL segment will act as the strategic partner for each project from development to implementation, including:
- Funding the project
- Contributing field experience and knowledge
- Providing required development and pilot testing infrastructure (whether at ICL’s TAMI facilities in Haifa, Israel or at one of its R&D facilities around the world);
- Close supervision and support by ICL’s top laboratory personnel and business executives; and
- Establishing a business development path for the project.
Today, ICL’s R&D organization includes approximately 500 employees that work at IMI/TAMI (ICL’s central institute for R&D located in Haifa, Israel) and at its other R&D facilities located in Germany, Holland, the U.S. and elsewhere in Israel.
##
About ICL
ICL is one of the world’s leading fertilizer and specialty chemicals companies. For a world challenged by population growth and scarce resources, ICL makes products that increase global food and water supplies and improve industrial materials and processes.
ICL produces approximately a third of the world’s bromine and is the 6th largest potash producer in the world. ICL is a leading supplier of fertilizers in Europe and a major player in specialty fertilizer market segments. One of the world’s most integrated manufacturers and suppliers of phosphate products, ICL has become the world’s leading provider of pure phosphoric acid and a major specialty phosphate player.
ICL is comprised of three core segments: ICL Fertilizers, ICL Industrial Products and ICL Performance Products. Its major production activities are located in Israel, Europe, the US, South America and China, and are supported by major global marketing and logistics networks. ICL's shares are traded on the Tel Aviv Stock Exchange (TASE: ICL). For more information, visit www.icl-group.com
About TAMI/IMI
IMI TAMI is the research and development arm of ICL. Its state-of-the-art R&D campus located in Haifa, Israel, contains advanced research, analytical and testing laboratories, GMP compliant facilities, a modern mini-pilot and pilot plants for process development and small scale production activities. IMI/TAMI also undertakes projects for other chemical and pharmaceutical companies world-wide. IMI TAMI has been granted ISO 9001, ISO 14001 and ISO 18001 approvals from the Standards Institution of Israel. Its laboratories are also approved for operation under the principles of GLP, as well as ISO/IEC 17025 approved for some analytical procedures. For more information, visit www.tami-imi.com
